Member Info for Moneymunch

Rob Clarke

@RobClarkeLab

·

19m

It was great to welcome 5 new students to our group this morning and made for our biggest Zoom lab meeting so far.

@MCRCnews

@UoM_DCS

PhD students funded by

@CRUKManchester

@The_MRC

@EvgenPharma

https://mobile.twitter.com/robclarkelab?lang=en

Good news coming..........Soon!!! Gla :-)

FFS the share options are part of his employment package, the same that any CEO would get in joining any listed company, and now the new CEO is incentivised to grow the company...On and UP!!! Gla holders...Good news stacking UP....Evgen will be moving UP significantly soon enough and is all set go...;-)))

Incentives in place for the new CEO to get the ball rolling. Gla ;-)

Since SFX-01 was selected for Covid-19 patient trials because of its Nrf2 activation, it now looks like that its STAT3 activator properties could also be of benefit against Covid-19....and so maybe a dual mechanism for SFX-01 as an Nrf2 activator and also STAT3 activator as a potent therapy against ARDS ....Gl ;-)

19/9/20

J Cell Mol Med. 2020 Sep 19. doi:

10.1111/jcmm.15838. Online ahead of print.

ABSTRACT

The SARS-coronavirus 2 is the aetiologic agent COVID-19. ACE2 has been identified as a cell entry receptor for the virus. Therefore, trying to understand how the gene is controlled has become a major goal. We silenced the expression of STAT3a and STAT3ß, and found that while silencing STAT3a causes an increase in ACE2 expression, silencing STAT3ß causes the opposite effect. Studying the role of STAT3 in ACE2 expression will shed light on the molecular events that contribute to the progression of the disease and that the different roles of STAT3a and STAT3ß in that context must be taken in consideration. Our results place STAT3 in line with additional potential therapeutic targets for treating COVID-19 patients.

hTtps://www.google.com/amp/s/www.docwirenews.com/abstracts/stat3-isoforms-differentially-affect-ace2-expression-a-potential-target-for-covid-19-therapy/amp/

ps and not forgetting the very recent WOW discovery of STAT3 being the "Key to immune system inflammation discovered"....and so plenty of mileage one would have thought. Gl ;-)

https://www.miragenews.com/key-to-immune-system-inflammation-discovered/

SFX-01 has been selected fot Covid-19 patient trials because industry and academia believe it could be a potent therapy for ARDS...Covid-19 is secondary in its potential but obviuosly the majority of severe Covid-19 patients die from ARDS related problems....and so potentially SFX-01 for ARDS related diseases will be around long after Covid-19 is defeated....although personally i think Covid-19 will be around for many years , regardless of any vaccine....Gla ;-)

General Information about ARDS

Acute respiratory distress syndrome (ARDS) is defined as an acute process, which results in moderate to severe loss of lung function.

Approximately 150,000-200,000 Americans will be diagnosed with ARDS each year. Worldwide, that number is approximately 2.2 million.

There is no known prevention for ARDS at the present time. Nor is there any known cure. ARDS patients are treated with supportive care, most often in the Intensive Care Unit.

Although ARDS is always a critical syndrome, more than half of the patients who are diagnosed with ARDS survive.

https://www.thoracic.org/patients/lung-disease-week/2011/ards-week/general-info.php

Lol dexamethasone is a steroid and therefore has many unpleasent side effects.......SFX-01 has a proven safety profile and is in evaluation for multiple disease targets, including breast cancer where phase 2 results were outstanding and life changinging for some patients.....it has also been selected for Covid-19 patient trials because industry and academia believe it could be a potent therapy for ARDS, Accute Respiratory Distress Syndrome, associated with Covid-19. Gla holders, the new CEO should be in place this coming week and every chance of significant reporting on SFX-01's pipeline will follow as well as a high chance of a strategic investor JV partnership....On and UP!!! ;-)

The following side effects are common (occurring in greater than 30%) for patients taking dexamethasone:

Increased appetite
Irritability
Difficulty sleeping (insomnia)
Swelling in your ankles and feet (fluid retention)
Heartburn
Muscle weakness
Impaired wound healing
Increased blood sugar levels. (Persons with Diabetes may need to have blood sugar levels monitored more closely and possible adjustments to diabetes medications).

The following are less common side effects (occurring in >10%) for patients receiving dexamethasone:

Headaches
Dizziness
Mood swings
Cataracts and bone thinning (with long-term use)

Evgen Pharma PLC University of Rochester Collaboration

13/02/2020

Professor Le and colleagues have previously published research showing an association between CKD patients with the GSTM1 null allele and more rapid CKD progression, and also that consumption of cruciferous vegetables (a source of sulforaphane) is associated with lower risks of kidney failure, with stronger effects in those having the GSTM1 null allele. On this basis, Professor Le approached Evgen, the developer of SFX-01, a stable form of sulforaphane that has demonstrated excellent safety and tolerability in previous clinical trials.

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

https://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-University-of-Rochester-Collabora/81743058

Lol viable......you post as much as you like mate as long it's relevenant to proceedings and in response to information and research posted, it's only d1ckheads like radar who aren't invested and hasn't got anything positive to say on any Lse share forum let alone EVG that won't appreciate it....Gl ;-)

Ps the US are more than interested in SFX-01....;-)

The following reasearch paper was released November 2019 by the highly prestigous University of Rochester in New York, and 3 months later they signed a MoU with Evgen to undertake a clinical trial on SFX-01 in patients with CKD and strongly illustrates the high regard that the industry has for SFX-01's potential over multiple disease targets.....Development news could drop at anytime, on another potential transformational blockbuster. Gla ;-)
........................

GSTM1 Deletion Exaggerates Kidney Injury in Experimental Mouse Models and Confers the Protective Effect of Cruciferous Vegetables in Mice and Humans

November 2019

Significance Statement

GSTM1 encodes a member of a superfamily of antioxidant enzymes, and a highly prevalent GSTM1 deletion variant is associated with kidney disease progression in two human study cohorts. In this study, the authors demonstrate that Gstm1 knockout mice exhibit increased oxidative stress, kidney injury, and inflammation in models of CKD and hypertension, and that Gstm1 loss in the parenchyma but not in bone marrow–derived cells drives renal inflammation. Importantly, consumption of broccoli powder or cruciferous vegetables was protective against kidney disease only in Gstm1 knockout mice, and was observed mainly in the human participants in the Atherosclerosis Risk in Communities Study who were homozygous for GSTM1 deletion. These findings suggest that targeting antioxidant therapy specifically in individuals carrying the GSTM1 deletion variant may be effective in delaying kidney disease progression.

hTtps://jasn.asnjournals.org/content/31/1/102.abstract

SFX-01's Covid-19 trials top of the list on Prof Chalmers Project Research website and now with a start date of 1/10/20, and so hopefully confirmation is imminent that the first patients have been administered and the patient trials are finally underway.....maybe a box of SFX-01 has been sent across the pond just incase
Remdesivir doesn't work out for the President. Gla ;-)

A randomized controlled trial of SFX-01 to improve clinical outcomes in COVID-19 patients (STAR-COVID)

Chalmers, J. & Dinkova-Kostova, A.

LifeArc

effective Start Date 1/10/20 ? End Date 30/09/21

Project: Research

Funding

LifeArc: £370,246.00

https://discovery.dundee.ac.uk/en/persons/james-chalmers

The new CEO is expected to join the BoD "early October" , and so next week in my book....let's hope he has plenty to report and fingers crossed his remit as CEO is more than just the development of SFX-01 across multiple disease targets...Evgen is all set for some serious growth imho and on a one way trajectory from small cap to mid cap player....with the very real chance of a M & A strategic investor / commercial JV partner in the pipeline....$$$$....Gla ;-)

"completed tens of M&A transactions and managed many drug development programmes"

University of Dundee

Can activation of NRF2 be a strategy against COVID-19?

......................

Sulforaphane

The isothiocyanate sulforaphane (SFN), originally isolated from broccoli, a cruciferous vegetable,as an inducer of the classical NRF2 target,NAD(P)H:quinone oxidoreductase 1(NQO1) [76],is the most potent naturally occurring NRF2 activator, with well-documented antioxidant and anti-inflammatory effects [77].

The highbioavailabilityof SFN and its stabilizeda-cyclodextrin-encapsulated version sulforadex (SFX-01) makes it an excellent candidate for alleviating exces-sive anti-inflammatory responses and protecting the lungs.

SFN has been found to be protectivein animal models of respiratory disease, including an ARDS model in rabbits [78] and a hyperoxia-induced pulmonary injury model in mice [79]. It also limits RSV replication and virus-inducedinflammation in the lungs of wild-type, but not NRF2-null, mice [80]. In HIV-1 transgenic rats,SFN increased GSH levels and the expression of NQO1, and restored the tight junctions betweenthe alveolar epithelial cells [81].

In anin vitromodel of influenza A infection, SFN reduced both viralcell entry and replication [82]. In addition, SFN suppresses HCV replication [83] and reducesHSV-1 virion production [29]. Interestingly, SFN inhibits nucleotide-binding oligomerization domain(NOD)-, leucine-rich repeat (LRR)-, and pyrin domain-containing protein (NLRP) 1 and 3 inflammasomes (crucial innate immune components that shape host immune homeostasis) aswell as pyroptosis, partly in an NRF2-independent manner [84].

Moreover, an interesting study con-ducted in smokers (a patient cohort with higher risk of lung infections, damage etc.) showed that SFN increased the expression of NQO1 in cells of nasal lavage fluid and, upon infection with live at-tenuated influenza virus, lowered the levels of IL-6 and viral load [85]

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjMs5fNn5XsAhUAQhUIHZ0YAbMQFjADegQIAhAC&url=https%3A%2F%2Fdiscovery.dundee.ac.uk%2Ffiles%2F51401086%2FPIIS0165614720301656.pdf&usg=AOvVaw0WtlAx4Wv2YupkSvpsJMAf

and SFX-01's panacea potential for the good of all mankind.......Gl ;-)

Ps radar, how old are you...ha ha ha....do you know a good Ozone Lawyer......ho ho ho ;-)

radar

Posted in: BP.

Posts: 3,208

Price: 225.10

No Opinion

RE: Damage has been done01 Oct 2020 09:25

Try telling your story to the drought ravaged regions of Africa and the areas of South East Asia where there is flooding the likes of which was never before seen.

Try telling your story to the folk whom live in the towns in the UK that were flooded a few months ago.

Try telling your story to nature that lived in Antartic where the ice has melted so much in the last two decades.

Trey telling your story to the scientists that understand the damage that has been done to the ozone lawyer.

Trade your greed for the good of the generations that are to follow.

It's folk with your attitude that create problems for all of mankind.

Lol.....have you read any of them you clueless numptie apart from the heeeehaaaa one addressed to you...ha ha ha:-)

Ps the sp finished 7% UP on the back of my first post this morning....Ker-Ching....and you're going to hate what's coming ....ho ho ho....get back under your stone you sad creature. :-)

Well done viable, I'm sure any educated guess will become clearer when the new CEO provides an update on proceedings. Gl :-)

Courtesy of Bumpa on Adfvn...:-)

More on the new CEO...

”
Dr Huw Jones

Non-Executive Director

Huw is Executive Chairman of Chronos Therapeutics in Oxford UK and strategic advisor to Gen 2 neuroscience in Cambridge UK. During his time at Chronos he extracted the company from Oxford University, raised substantial grant and equity finance and led Chronos’ acquisition of three early research programmes in brain disease from Shire PLC. He was surprised and pleased to have been awarded European CEO of the year 2016/17 for drug discovery by European CEO Magazine, alongside leaders in their sectors from Adidas, Unilever and Spotify. Huw advises Gen 2 Neuroscience in Cambridge, UK. Gen2 has a unique technology targeting dementias and tauopathies and is funded by the UK Dementia Discovery fund.

Previous posts include: NED, then rescue CEO, Ardana PLC; non–executive chairman, Ashbourne Pharmaceuticals; president Europe, CV Therapeutics Inc; SVP, Elan Pharmaceuticals and various roles of increasing responsibility at SmithKline Beecham (GSK). In his varied career he has launched dozens of new medicines in several countries, completed tens of M&A transactions and managed many drug development programmes. Huw holds a PhD in neuropharmacology from the University of Birmingham, he is a passionate SCUBA diver and wine lover but never combines the two.”

1 x 300k and 1 x250k both at 12.30p....Looks like the share accumulation continues imho,...a disclosure on events could be close now the new CEO has been announced...this will go ballistic if a strategic investor is the reason behind the share transfers/ accumulation over several months...Gla :-

Evgen is all set for a significant re-rate or two as good news rolls in from this current bargain low....SFX-01 in evaluation for multiple disease targets with high profile academic researchers, with phase 2b trials for breast cancer in the planning as well as the phase 2/3 Covid-19 trials....the current lowly market cap does not reflect true and fair value of the current development status of SFX-01 , especially with similar stage Bio's valued at $100's of millions....and so hopefully the new CEO will be the catalyst for full appreciation and significant and substantial returns....BIG pharma could also be a pivotal factor in proceedings. Gl :-)

https://www.google.com/amp/s/surfaceyourrealself.com/2020/08/06/sulforaphane-clinical-trials-and-covid-19/amp/

Prof Chalmers..lead investigator for SFX-01 Covid-19 patient trials. Gla :-)

James D Chalmers

@ProfJDChalmers

·

2h

Current R0 estimate in Scotland is 1.2 to 1.6 (approx. 3.7 in March/April). Anything above 1 means cases continue to rise. The best option is to get the number below 1 - that means sustainable control of the virus. A circuit break means a temporary drop to 0.5/0.6

1

2

4

Show this thread

James D Chalmers

@ProfJDChalmers

·

2h

Nice to talk to #bbcgms

@BBCScotlandNews

about the latest COVID19 figures in Scotland. The problem with a "circuit break" i.e temporary lockdown is that its an acknowledgement we can't control the virus. Likely therefore to mean more "circuit breakers" e.g over Christmas